Gerhard Winter - Concepedia

Author

Gerhard Winter

Ludwig-Maximilians-Universität München ORCID

Also Known As

G Winter, G. C. B. WINTER, G. C. B. Winter, G. WINTER, G. Winter, G.C.B Winter, G.C.B. Winter, GERHARD WINTER, Gal Winter, Gerhard WINTER

343

Publications

14.5K

Citations

H-Index

239

Concepts

All Affiliations

Ludwig-Maximilians-Universität München Technical University of Munich Boehringer Ingelheim (Germany)Roche Pharma AG (Germany)

About

Gerhard Winter is an author at Ludwig-Maximilians-Universität München specializing in medicine, engineering, and biomedical engineering.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	42	99	6.1K
2	Engineering	37	72	3.9K
3	Natural Sciences	21	24	1.5K
4	Health Sciences	5	5	311
5	Education	3	3	80

Gerhard Winter

186

Publications

10.4K

Citations

H-Index

Page 1

	Year	Citations
Overlooking Subvisible Particles in Therapeutic Protein Products: Gaps That May Compromise Product Quality John F. Carpenter, Theodore W. Randolph, Wim Jiskoot, Journal of Pharmaceutical Sciences Protein ChemistryBiochemistrySubvisible ParticlesProtein FoldingTherapeutic Protein Products	2008	578
Protein Instability and Immunogenicity: Roadblocks to Clinical Application of Injectable Protein Delivery Systems for Sustained Release Wim Jiskoot, Theodore W. Randolph, David B. Volkin, Journal of Pharmaceutical Sciences VaccinationSustained ReleaseProtein InstabilityImmunologyClinical Application	2011	248
Human Fc gamma RI and Fc gamma RII interact with distinct but overlapping sites on human IgG John Lund, Gerhard Winter, Peter Jones, The Journal of Immunology	1991	205
Potential inaccurate quantitation and sizing of protein aggregates by size exclusion chromatography: Essential need to use orthogonal methods to assure the quality of therapeutic protein products John F. Carpenter, Theodore W. Randolph, Wim Jiskoot, Journal of Pharmaceutical Sciences Potential Inaccurate QuantitationOrthogonal MethodsProtein AggregatesProtein PurificationBioanalysis	2009	202
Lyophilized Drug Product Cake Appearance: What Is Acceptable? Sajal M. Patel, Steven L. Nail, Michael J. Pikal, Journal of Pharmaceutical Sciences BiomanufacturingExcipientsActive IngredientPharmacologyPharmaceutical Technology	2017	199
SURFIN is a polymorphic antigen expressed on <i>Plasmodium falciparum</i> merozoites and infected erythrocytes Gerhard Winter, Satoru Kawai, Malin Haeggström, The Journal of Experimental Medicine Polymorphic AntigenParasitic ProtozoaMedicineGeneticsPathogenesis	2005	192
Charge-mediated influence of the antibody variable domain on FcRn-dependent pharmacokinetics Angela Schoch, Hubert Kettenberger, Olaf Mundigl, Proceedings of the National Academy of Sciences Immunocytochemical TechniqueImmunologyImmune SystemImmunotherapyFcrn Affinity Chromatography	2015	191
Microencapsulation of rh-erythropoietin, using biodegradable poly(d,l-lactide-co-glycolide): protein stability and the effects of stabilizing excipients Michael M. Morlock, Hans Koll, Gerhard Winter, European Journal of Pharmaceutics and Biopharmaceutics EngineeringProtein StabilityBiomaterials DesignBiotechnologyMicro-encapsulation	1997	186
Quantitation of Aggregate Levels in a Recombinant Humanized Monoclonal Antibody Formulation by Size-Exclusion Chromatography, Asymmetrical Flow Field Flow Fractionation, and Sedimentation Velocity John P. Gabrielson, Mark L. Brader, Allen H. Pekar, Journal of Pharmaceutical Sciences Sedimentation VelocityAggregate LevelsSize-exclusion ChromatographyEngineeringMedicine	2006	173
Recombinant spider silk particles as drug delivery vehicles Andreas Lammel, Martin E. Schwab, Markus Höfer, Biomaterials NanomedicineEngineeringDrug Delivery SystemsBiomedical EngineeringDrug Delivery System	2010	162

Page 1